RU486 did not exacerbate cytokine release in mice challenged with LPS nor in db/db mice

BMC Pharmacology

Volumn 8, Issue , 2008, Pages

  Yang, Baichun ^a   Trump, Ryan P ^a   Shen, Ying ^a   McNulty, Judi A ^a   Clifton, Lisa G ^a   Stimpson, Stephen A ^a   Lin, Peiyuan ^a   Pahel, Greg L ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTERONE; CORTICOTROPIN; CYTOKINE; GLUCOCORTICOID; GLUCOSE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MIFEPRISTONE; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; ANTIDIABETIC AGENT; CCL2 PROTEIN, MOUSE; GLUCOCORTICOID RECEPTOR; GLUCOSE 6 PHOSPHATASE; HORMONE ANTAGONIST; LEPTIN RECEPTOR; PHOSPHOENOLPYRUVATE CARBOXYLASE KINASE; PROTEIN SERINE THREONINE KINASE;

AKR MOUSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; C57BL MOUSE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOTROPIN BLOOD LEVEL; CYTOKINE RELEASE; DIET; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; MALE; MOUSE; NONHUMAN; OBESITY; ANIMAL; BLOOD; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LIVER; METABOLISM; MOUSE MUTANT; NON INSULIN DEPENDENT DIABETES MELLITUS;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; BLOOD GLUCOSE; CHEMOKINE CCL2; CORTICOSTERONE; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOSE-6-PHOSPHATASE; HORMONE ANTAGONISTS; HYPOGLYCEMIC AGENTS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MIFEPRISTONE; OBESITY; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, GLUCOCORTICOID; RECEPTORS, LEPTIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 44349168856     PISSN: None     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-8-7     Document Type: Article

References (40)

1. Garrel DR Moussali R De Oliveira A Lesiege D Lariviere F RU 486 prevents the acute effects of cortisol on glucose and leucine metabolism J Clin Endocrinol Metab 1995, 80:379-385 10.1210/jc.80.2.379 7888013
2. Jacobson PB von Geldem TW Ohman L Osterland M Wang J Zinker B Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes J Pharm Exper Thera 2005, 314:191-200 10.1124/ jpet.104.081257
3. Holsboer F Therapeutics for depression and anxiety disorders Drug Discovery Today: Therapeutic Strategies 2004, 1:105-109 10.1016/ j.ddstr.2004.08.012
4. Miech RP Pathophysiology of mifepristone-induced septic shock due to Clostridium Sordellii Ann Pharmacother 2005, 39:1483-1488 10.1345/ aph.1G189 16046483
5. Annane D Cavaillon J Corticosteroids in sepsis: From bench to bedside? Shock 2003, 20:197-207 10.1097/01.shk.0000079423.72656.2f 12923489
6. Webster JI Sternberg EM Role of the hypothalamic-pituitary-adrenal axis, glucocorticoids and glucocorticoid receptors in toxic sequelae of exposure to bacterial and viral products Journal of Endocrinology 2004, 181:207-221 10.1677/joe.0.1810207 15128270
7. Gaillard RC Interaction between the hypothalamo-pituitary-adrenal axis and the immunological system Ann Endocrinol (Paris) 2001, 62(2):155-163 11353887
8. Williamson DR Lapointe M The hypothalamic-pituitary-adrenal axis and low-dose glucocorticoids in the treatment of septic shock Pharmacotherapy 2003, 23:514-525 10.1592/phco.23.4.514.32123 12680481
9. Leonhardt A Boonyaratanakornkit V Edwards DP Progesterone receptor transcription signaling mechanisms Steroids 2003, 68:761-770 10.1016/ S0039-128X(03)00129-6 14667966
10. Gettys TW Watson PM Taylor IL Collins S RU-486 (Mifepristone) ameliorates diabetes but does not correct deficient beta-adrenergic signaling in adipocytes from mature C57BL/6J-ob/ob mice Int J Obes Relat Metab Disord 1997, 21:865-873 10.1038/sj.ijo.0800479 9347404
11. Hawes AS Rock CS Keogh CV Lowry SF Calvano SE In vivo effects of the antiglucocorticoid RU486 on glucocorticoid and cytokine responses to Escherichia Coli endoxin Infect Immun 1992, 60:2641-2647 257215 1612734
12. Gaillard RC Riondel A Muller AF Herrmann W Baulieu EE RU486: A steroid with antiglucocorticoid activity that only disinhibits the human pituitary-adrenal system at a specific time of day Proc Natl Acad Sci USA 2006, 81:3879-3882 10.1073/pnas.81.12.3879
13. Lazar G Jr Duda E Lazar G Effect of RU 38486 on TNF production and toxicity FEBS letters 1992, 308:137-140 10.1016/0014-5793(92)81261-J 1499722
14. Danco Laboratories Danco Laboratories announced today that it is modifying the labeling for Mifeprex to include updated safety information 7-18-2005
15. FDA Public Health Advisory Sepsis and Medical Abortion 2005
16. Sinave C LeTemplier G Blouin D Leveilli F Deland E Toxic shock syndrome due to Clostridium sordellii: A dramatic postpartum and postabortion disease Clin Infect Dis 2002, 35:1441-1443 10.1086/344464 12439811
17. Morris M Grossman A The Medical Management of Cushing's Syndrome Ann New York Acad Sci 2002, 970:119-133
18. Nieman LK Chrousos GP Kellner C Spitz IM Nisula BC Cutler GB Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486 J Clin Endocrinol Metab 1985, 61:536-540 2991327
19. Sartor O Cutler GB Jr Mifepristone: Treatment of Cushing's Syndrome [New Applications of Mifepristone (RU 486)] Clinical Obstetrics and Gynecology 1996, 39:506-510 10.1097/00003081-199606000-00024
20. Spitz IM Bardin CW Mifepristone (RU 486) - A Modulator of Progestin and Glucocorticoid Action New Engl J Med 1993, 329:404-412 10.1056/ NEJM199308053290607 8326975
21. Kettel LM Murphy AA Morales AJ Ulmann A Baulieu EE Yen SS Treatment of endometriosis with the antiprogesterone mifepristone (RU486) Fertil Steril 1996, 66:669-670 8816639
22. University of Rochester Medical Center Rochester Study Rolls Out RU-486 To Treat Uterine Fibroids 2006
23. Link JT Sorensen B Patel J Grynfarb M Goos-Nilsson A Wang J Antidiabetic Activity of Passive Nonsteroidal Glucocorticoid Receptor Modulators J Med Chem 2005, 48:5295-5304 10.1021/jm050205o 16078847
24. Lamping N Dettmer R Schröder NWJ Pfeil D Hallatschek W Burger R LPS-binding Protein Protects Mice from Septic Shock Caused by LPS or Gram-negative Bacteria J Clin Invest 1998, 101:2065-2071 508794 9593762 10.1172/JCI2338
25. Rivest S How circulating cytokines trigger the neural circuits that control the hypothalamic-pituitary-adrenal axis Psychoneuroendocrinology 2001, 26:761-788 10.1016/S0306-4530(01)00064-6 11585678
26. Marx C The systemic adrenal stress response in severe sepsis and critical illness Clin Intensive Care 2005, 16:57-64 10.1080/ 09563070500061422
27. Xu H Barnes GT Yang Q Tan G Yang D Chou CJ Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance J Clin Invest 2003, 112:1821-1830 296998 14679177
28. Wellen KE Hotamisligil GS Inflammation, stress, and diabetes J Clin Invest 2005, 115:1111-1119 1087185 15864338
29. Ahrén B Simonsson E Scheurink AJ Mulder H Myrsén U Sundler F Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice Metabolism 1997, 46:97-106 10.1016/S0026-0495(97)90175-X 9005977
30. Nordeen SK Bona BJ Moyer ML Latent agonist activity of the steroid antagonist, RU486, is unmasked in cells treated with activators of protein kinase A Mol Endocrin 1993, 7:731-742 10.1210/me.7.6.731
31. Zhang S Jonklaas J Danielsen M The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values Steroids 2007, 72:600-608 10.1016/ j.steroids.2007.03.012 17509631
32. Schulz M Eggert M Baniahmad A Dostert A Heinzel T Renkawitz R RU486-induced glucocorticoid receptor agonism is controlled by the receptor N terminus and by corepressor binding J Biol Chem 2002, 277:26238-26243 10.1074/jbc.M203268200 12011091
33. Donaldson MS Dorflinger L Brown SS Benet LZ Clinical Applications of Mifepristone (RU486) and Other Antiprogestins Washington DC: National Academies Press 1993
34. Davies D Dai D Wolf DM Leslie KK Immunomodulatory and transcriptional effects of progesterone through progesterone A and B receptors in Hec50co poorly differentiated endometrial cancer cells J Society Gyn Invest 2004, 11:494-499 10.1016/j.jsgi.2004.04.003
35. Davies S Dai D Feldman I Pickett G Leslie KK Identification of a novel mechanism of NF-kappaB inactivation by progesterone through progesterone receptors in Hec50co poorly differentiated endometrial cancer cells: induction of A20 and ABIN-2 Gynecol Oncol 2004, 94:463-470 10.1016/ j.ygyno.2004.05.028 15297189
36. Elovitz M Wang Z Medroxyprogesterone acetate, but not progesterone, protects against inflammation-induced parturition and intrauterine fetal demise Am J Ob Gyn 2004, 190:693-701 10.1016/j.ajog.2003.10.693
37. Tibbetts TA Conneely OM O'Malley BW Progesterone via its receptor antagonizes the pro-inflammatory activity of estrogen in the mouse uterus Biol Reproduction 1999, 60:1158-1165 10.1095/biolreprod60.5.1158
38. Strain Name: AKR/J http://jaxmice.jax.org/strain/000648.html
39. Chirgwin JM Przybyla AE MacDonald RJ Rutter WJ Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease Biochemistry 1979, 18:5294-5299 10.1021/bi00591a005 518835
40. Bustin S Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays J Mol Endocrinol 2000, 25:169-193 10.1677/jme.0.0250169 11013345